Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • Beta-Amyloid (1-11) Research Applications, Clinical Value, a

    2025-08-04

    Beta-Amyloid (1-11): Research Applications, Clinical Value, and Future Directions in Neurodegenerative Disease Studies

    Introduction
    Beta-Amyloid (1-11) is a synthetic peptide fragment corresponding to the N-terminal residues 1 through 11 of the full-length amyloid-beta (Aβ) peptide, a key molecular player in the pathogenesis of Alzheimer’s disease (AD) and related neurodegenerative disorders. The Aβ peptide is generated by the sequential proteolytic cleavage of amyloid precursor protein (APP) by β- and γ-secretases, resulting in peptides of varying lengths, most notably Aβ1-40 and Aβ1-42 (Selkoe & Hardy, 2016, EMBO Mol Med). The N-terminal region, represented by Beta-Amyloid (1-11), is critical for understanding the initial aggregation events and immunogenic properties of Aβ peptides.

    Mechanistically, Beta-Amyloid (1-11) serves as a model peptide for studying the early stages of amyloid aggregation, epitope mapping for antibody development, and as a tool for investigating the biochemical and immunological properties of Aβ. Its relatively short sequence allows for detailed structural and functional analyses, facilitating the development of diagnostic and therapeutic strategies targeting the amyloidogenic process (Walsh & Selkoe, 2007, Neuron).

    [Related: jib-04] Clinical Value and Applications
    The clinical value of Beta-Amyloid (1-11) lies primarily in its utility as a research tool rather than as a direct therapeutic agent. Its applications span several domains:

    1. **Epitope Mapping and Antibody Development:** Beta-Amyloid (1-11) is frequently used to map the N-terminal epitopes recognized by monoclonal antibodies, which are critical for immunotherapy and diagnostic assay development (Seubert et al., 1992, Nature).
    2. **Aggregation Studies:** The peptide provides a simplified system to study the initial nucleation events in Aβ aggregation, which are believed to be central to the formation of neurotoxic oligomers and fibrils in AD (Jarrett & Lansbury, 1993, Cell).
    3. **Biomarker Discovery:** As the N-terminal region is often targeted in cerebrospinal fluid (CSF) and plasma biomarker assays, Beta-Amyloid (1-11) is used as a standard or calibrator in immunoassays (Blennow et al., 2015, Nat Rev Neurol).
    4. **Immunological Studies:** The peptide is instrumental in evaluating T-cell and B-cell responses to Aβ, which has implications for vaccine development and understanding neuroinflammation in AD (Monsonego et al., 2003, Proc Natl Acad Sci USA).
    5. **Structure-Activity Relationship (SAR) Analyses:** By isolating the N-terminal segment, researchers can dissect the contributions of specific residues to aggregation propensity and toxicity (Crescenzi et al., 2002, J Biol Chem).

    [Related: mirdametinib package insert] Key Challenges and Pain Points Addressed
    Current challenges in Alzheimer’s disease research and therapy include the lack of early diagnostic markers, limited understanding of the initial aggregation mechanisms, and the need for highly specific immunotherapeutic agents. Beta-Amyloid (1-11) addresses several of these pain points:

    - **Specificity in Antibody Development:** Full-length Aβ peptides present multiple epitopes, complicating the development of antibodies with high specificity. Beta-Amyloid (1-11) enables the generation and validation of antibodies targeting the N-terminal region, which is less prone to post-translational modifications and truncations (Seubert et al., 1992, Nature).
    - **Simplification of Aggregation Studies:** The complexity of full-length Aβ aggregation can obscure mechanistic insights. The shorter Beta-Amyloid (1-11) fragment allows for controlled studies of nucleation and early oligomerization events (Jarrett & Lansbury, 1993, Cell).
    - **Standardization in Biomarker Assays:** Variability in Aβ species complicates assay calibration. Beta-Amyloid (1-11) serves as a standardized reagent for quantifying N-terminal Aβ in biological samples (Blennow et al., 2015, Nat Rev Neurol).
    - **Immunological Profiling:** The peptide facilitates the study of immune responses to specific Aβ epitopes, informing vaccine design and immunomodulatory strategies (Monsonego et al., 2003, Proc Natl Acad Sci USA).

    [Related: y27632 inhibitor] Literature Review
    A growing body of literature underscores the importance of the N-terminal region of Aβ and the utility of Beta-Amyloid (1-11) in research:

    1. **Seubert et al. (1992, Nature):** This seminal study demonstrated that monoclonal antibodies targeting the N-terminal residues of Aβ could selectively recognize amyloid plaques in AD brain tissue, highlighting the diagnostic and therapeutic potential of N-terminal epitopes.
    2. **Jarrett & Lansbury (1993, Cell):** The authors elucidated the nucleation-dependent polymerization mechanism of Aβ, emphasizing the role of the N-terminal region in the initial aggregation process.
    3. **Crescenzi et al. (2002, J Biol Chem):** Using NMR spectroscopy, this study characterized the structural properties of Aβ fragments, including residues 1-11, revealing their contribution to the conformational dynamics of the full-length peptide.
    4. **Monsonego et al. (2003, Proc Natl Acad Sci USA):** The immunogenicity of Aβ peptides was investigated, with Beta-Amyloid (1-11) being used to map T-cell epitopes and assess immune responses in AD patients and animal models.
    5. **Blennow et al. (2015, Nat Rev Neurol):** This review highlighted the use of N-terminal Aβ fragments as biomarkers in CSF and plasma, with Beta-Amyloid (1-11) serving as a reference standard in assay development.
    6. **Walsh & Selkoe (2007, Neuron):** The authors reviewed the toxic effects of Aβ oligomers, noting the significance of the N-terminal region in mediating synaptic dysfunction.
    7. **Selkoe & Hardy (2016, EMBO Mol Med):** This comprehensive review discussed the amyloid hypothesis and the central role of Aβ in AD, with emphasis on the molecular diversity of Aβ species.

    Experimental Data and Results
    Experimental studies utilizing Beta-Amyloid (1-11) have yielded several key findings relevant to AD research:

    - **Antibody Specificity:** Seubert et al. (1992) generated monoclonal antibodies against Beta-Amyloid (1-11) and demonstrated their ability to selectively stain amyloid plaques in post-mortem AD brain tissue, validating the utility of this fragment for immunohistochemical applications.
    - **Aggregation Kinetics:** Jarrett & Lansbury (1993) showed that the N-terminal region, while not sufficient for fibril formation on its own, modulates the aggregation kinetics of longer Aβ fragments, suggesting a regulatory role in nucleation.
    - **Structural Insights:** Crescenzi et al. (2002) used NMR to reveal that Beta-Amyloid (1-11) adopts a flexible conformation in solution, which may facilitate interactions with other Aβ molecules or cellular components.
    - **Immunogenicity:** Monsonego et al. (2003) demonstrated that Beta-Amyloid (1-11) contains T-cell epitopes capable of eliciting immune responses in both mice and humans, providing a basis for vaccine development.
    - **Assay Calibration:** Blennow et al. (2015) reported the use of Beta-Amyloid (1-11) as a calibrator in ELISA-based assays for quantifying Aβ in CSF, contributing to the standardization of biomarker measurements.

    Collectively, these studies establish Beta-Amyloid (1-11) as a versatile tool for dissecting the molecular and immunological underpinnings of Aβ pathology.

    Usage Guidelines and Best Practices
    To maximize the utility of Beta-Amyloid (1-11) in research settings, the following guidelines are recommended:

    1. **Peptide Handling:** Beta-Amyloid (1-11) should be reconstituted in sterile, filtered water or appropriate buffer (e.g., PBS) at the recommended concentration (typically 1–5 mg/mL). Aliquots should be stored at –20°C to –80°C to prevent degradation or aggregation.
    2. **Aggregation Studies:** For aggregation assays, use freshly prepared peptide solutions and minimize freeze-thaw cycles. Employ thioflavin T fluorescence or transmission electron microscopy to monitor aggregation kinetics.
    3. **Immunoassays:** When using Beta-Amyloid (1-11) as a standard or antigen, ensure proper coating of ELISA plates and optimize antibody concentrations to enhance specificity and sensitivity.
    4. **Epitope Mapping:** Utilize overlapping peptide arrays including Beta-Amyloid (1-11) Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 21 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11580655